Roche licensed a Chinese biotech's obesity drug in a deal worth up to $1.16 billion
The Swiss drugmaker will pay up to $100 million upfront to license an RNAi therapy targeting fat tissue from Shanghai-based Rona Therapeutics
We haven't written up this one. Quartz has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.